Literature DB >> 16421106

Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.

Rudi K Allan1, Danny Mok, Bryan K Ward, Thomas Ratajczak.   

Abstract

The C-terminal domain of Hsp90 displays independent chaperone activity, mediates dimerization, and contains the MEEVD motif essential for interaction with tetratricopeptide repeat-containing immunophilin cochaperones assembled in mature steroid receptor complexes. An alpha-helical region, upstream of the MEEVD peptide, helps form the dimerization interface and includes a hydrophobic microdomain that contributes to the Hsp90 interaction with the immunophilin cochaperones and corresponds to the binding site for novobiocin, a coumarin-related Hsp90 inhibitor. Mutation of selected residues within the hydrophobic microdomain significantly impacted the chaperone function of a recombinant C-terminal Hsp90 fragment and novobiocin inhibited wild-type chaperone activity. Prior incubation of the Hsp90 fragment with novobiocin led to a direct blockade of immunophilin cochaperone binding. However, the drug had little influence on the pre-formed Hsp90-immunophilin complex, suggesting that bound cochaperones mask the novobiocin-binding site. We observed a differential effect of the drug on Hsp90-immunophilin interaction, suggesting that the immunophilins make distinct contacts within the C-terminal domain to specifically modulate Hsp90 function. Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates. Novobiocin therefore acts locally and allosterically to induce conformational changes within multiple regions of the Hsp90 protein. We provide evidence that coumermycin A1, a coumarin structurally related to novobiocin, interferes with dimerization of the Hsp90 C-terminal domain. Coumarin-based inhibitors then may antagonize Hsp90 function by inducing a conformation favoring separation of the C-terminal domains and release of substrate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421106     DOI: 10.1074/jbc.M512406200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells.

Authors:  Takashi Imai; Yu Kato; Chiaki Kajiwara; Shusaku Mizukami; Ikuo Ishige; Tomoko Ichiyanagi; Masaki Hikida; Ji-Yang Wang; Heiichiro Udono
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Versatile TPR domains accommodate different modes of target protein recognition and function.

Authors:  Rudi Kenneth Allan; Thomas Ratajczak
Journal:  Cell Stress Chaperones       Date:  2010-12-09       Impact factor: 3.667

3.  A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.

Authors:  Mathias Riebold; Christian Kozany; Lee Freiburger; Michael Sattler; Michael Buchfelder; Felix Hausch; Günter K Stalla; Marcelo Paez-Pereda
Journal:  Nat Med       Date:  2015-02-09       Impact factor: 53.440

4.  Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities.

Authors:  Elisabetta Moroni; Huiping Zhao; Brian S J Blagg; Giorgio Colombo
Journal:  J Chem Inf Model       Date:  2014-01-15       Impact factor: 4.956

Review 5.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90.

Authors:  Tony Taldone; Victoria Gillan; Weilin Sun; Anna Rodina; Pallav Patel; Kirsty Maitland; Kerry O'Neill; Gabriela Chiosis; Eileen Devaney
Journal:  PLoS Negl Trop Dis       Date:  2010-06-15

9.  Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Authors:  Luciano Vozzolo; Belinda Loh; Paul J Gane; Maryame Tribak; Lihong Zhou; Ian Anderson; Elisabeth Nyakatura; Richard G Jenner; David Selwood; Ariberto Fassati
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

10.  Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer.

Authors:  Giulia Morra; Gennady Verkhivker; Giorgio Colombo
Journal:  PLoS Comput Biol       Date:  2009-03-20       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.